| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Child Abuse | 42 | 2024 | 1091 | 6.830 |
Why?
|
| Adult Survivors of Child Abuse | 9 | 2024 | 301 | 2.390 |
Why?
|
| Amygdala | 10 | 2023 | 1379 | 2.160 |
Why?
|
| Child Abuse, Sexual | 15 | 2016 | 401 | 1.850 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 20 | 2023 | 3730 | 1.630 |
Why?
|
| Hippocampus | 13 | 2023 | 3782 | 1.440 |
Why?
|
| Methylphenidate | 8 | 2022 | 480 | 1.390 |
Why?
|
| Mental Disorders | 15 | 2024 | 6876 | 1.230 |
Why?
|
| Stress, Psychological | 16 | 2020 | 4530 | 1.160 |
Why?
|
| Central Nervous System Stimulants | 10 | 2022 | 1170 | 1.120 |
Why?
|
| Brain | 35 | 2023 | 27453 | 1.010 |
Why?
|
| Functional Laterality | 10 | 2008 | 2267 | 1.010 |
Why?
|
| Motor Activity | 31 | 2020 | 2713 | 0.990 |
Why?
|
| Corpus Callosum | 4 | 2022 | 753 | 0.980 |
Why?
|
| Maternal Deprivation | 4 | 2019 | 40 | 0.960 |
Why?
|
| Stress Disorders, Post-Traumatic | 20 | 2024 | 4640 | 0.850 |
Why?
|
| Parent-Child Relations | 4 | 2013 | 773 | 0.840 |
Why?
|
| Nucleus Accumbens | 10 | 2000 | 358 | 0.830 |
Why?
|
| Bullying | 2 | 2019 | 234 | 0.800 |
Why?
|
| Circadian Rhythm | 29 | 2016 | 2593 | 0.780 |
Why?
|
| Domestic Violence | 3 | 2012 | 180 | 0.770 |
Why?
|
| Child | 75 | 2024 | 80960 | 0.760 |
Why?
|
| Punishment | 3 | 2016 | 95 | 0.760 |
Why?
|
| Adolescent | 68 | 2024 | 89244 | 0.750 |
Why?
|
| Prefrontal Cortex | 12 | 2023 | 2237 | 0.740 |
Why?
|
| Magnetic Resonance Imaging | 30 | 2023 | 36854 | 0.720 |
Why?
|
| Receptors, Dopamine D1 | 10 | 2003 | 277 | 0.710 |
Why?
|
| Attention | 11 | 2023 | 2423 | 0.680 |
Why?
|
| Limbic System | 6 | 2011 | 424 | 0.660 |
Why?
|
| Seasonal Affective Disorder | 9 | 2002 | 49 | 0.650 |
Why?
|
| Verbal Behavior | 2 | 2013 | 336 | 0.640 |
Why?
|
| Adolescent Development | 2 | 2016 | 279 | 0.640 |
Why?
|
| Paternal Deprivation | 1 | 2018 | 10 | 0.640 |
Why?
|
| Depressive Disorder | 16 | 2016 | 3723 | 0.620 |
Why?
|
| Self-Injurious Behavior | 2 | 2024 | 568 | 0.600 |
Why?
|
| Dopamine | 15 | 2010 | 1596 | 0.590 |
Why?
|
| Child Development | 4 | 2016 | 2336 | 0.580 |
Why?
|
| Corpus Striatum | 12 | 2004 | 1225 | 0.580 |
Why?
|
| Touch | 2 | 2020 | 316 | 0.580 |
Why?
|
| Young Adult | 37 | 2024 | 60131 | 0.570 |
Why?
|
| Aggression | 4 | 2013 | 750 | 0.570 |
Why?
|
| Diffusion Tensor Imaging | 4 | 2022 | 2426 | 0.550 |
Why?
|
| Visual Cortex | 4 | 2018 | 1112 | 0.550 |
Why?
|
| Cerebellum | 6 | 2010 | 1522 | 0.540 |
Why?
|
| Anomie | 1 | 2016 | 9 | 0.530 |
Why?
|
| Receptors, Dopamine | 10 | 2002 | 293 | 0.530 |
Why?
|
| Neurobiology | 4 | 2024 | 135 | 0.530 |
Why?
|
| Empathy | 1 | 2020 | 476 | 0.520 |
Why?
|
| Puberty | 1 | 2019 | 501 | 0.520 |
Why?
|
| Fear | 5 | 2023 | 1493 | 0.500 |
Why?
|
| Emigration and Immigration | 1 | 2018 | 407 | 0.490 |
Why?
|
| Male | 137 | 2024 | 365203 | 0.490 |
Why?
|
| Hyperkinesis | 2 | 2012 | 88 | 0.490 |
Why?
|
| Resilience, Psychological | 3 | 2018 | 807 | 0.490 |
Why?
|
| Neural Pathways | 5 | 2022 | 3120 | 0.490 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2017 | 451 | 0.480 |
Why?
|
| Psychopathology | 5 | 2023 | 434 | 0.470 |
Why?
|
| Self Concept | 1 | 2020 | 1046 | 0.470 |
Why?
|
| Actigraphy | 2 | 2016 | 527 | 0.470 |
Why?
|
| Receptors, Dopamine D2 | 7 | 2002 | 472 | 0.460 |
Why?
|
| Depressive Disorder, Major | 5 | 2022 | 4818 | 0.450 |
Why?
|
| Depression | 9 | 2024 | 8231 | 0.440 |
Why?
|
| Ketamine | 2 | 2017 | 527 | 0.440 |
Why?
|
| Female | 129 | 2024 | 397515 | 0.440 |
Why?
|
| Love | 1 | 2013 | 39 | 0.430 |
Why?
|
| Bipolar Disorder | 8 | 2022 | 5131 | 0.430 |
Why?
|
| Object Attachment | 1 | 2016 | 331 | 0.420 |
Why?
|
| Humans | 156 | 2024 | 768970 | 0.420 |
Why?
|
| Anisotropy | 4 | 2022 | 1295 | 0.410 |
Why?
|
| Affect | 4 | 2015 | 1500 | 0.400 |
Why?
|
| Rats | 52 | 2020 | 23786 | 0.390 |
Why?
|
| Neuronal Plasticity | 1 | 2020 | 1448 | 0.390 |
Why?
|
| Adult | 69 | 2024 | 223851 | 0.380 |
Why?
|
| Neuropsychological Tests | 9 | 2017 | 7148 | 0.380 |
Why?
|
| Rats, Sprague-Dawley | 18 | 2012 | 8144 | 0.370 |
Why?
|
| Memory, Long-Term | 1 | 2011 | 61 | 0.370 |
Why?
|
| Clathrin | 1 | 2012 | 258 | 0.360 |
Why?
|
| Adaptation, Physiological | 2 | 2016 | 1313 | 0.360 |
Why?
|
| Arousal | 10 | 2010 | 1183 | 0.360 |
Why?
|
| Alcoholism | 2 | 2019 | 1981 | 0.350 |
Why?
|
| Brain Chemistry | 6 | 2010 | 959 | 0.350 |
Why?
|
| Phototherapy | 5 | 2023 | 368 | 0.340 |
Why?
|
| Psychiatric Status Rating Scales | 13 | 2017 | 6030 | 0.330 |
Why?
|
| Visual Fields | 3 | 2008 | 1067 | 0.310 |
Why?
|
| Substance-Related Disorders | 7 | 2013 | 4423 | 0.310 |
Why?
|
| Brain Mapping | 10 | 2023 | 6739 | 0.290 |
Why?
|
| Psychomotor Performance | 5 | 2012 | 1894 | 0.290 |
Why?
|
| Sexual Maturation | 2 | 2002 | 258 | 0.290 |
Why?
|
| Developmental Disabilities | 2 | 2008 | 1520 | 0.290 |
Why?
|
| Visual Pathways | 2 | 2011 | 559 | 0.290 |
Why?
|
| Dominance, Cerebral | 7 | 2012 | 624 | 0.290 |
Why?
|
| Siblings | 1 | 2011 | 828 | 0.290 |
Why?
|
| Nerve Net | 2 | 2018 | 2359 | 0.280 |
Why?
|
| Organ Size | 5 | 2018 | 2268 | 0.280 |
Why?
|
| Hydrocortisone | 9 | 2019 | 1841 | 0.280 |
Why?
|
| Parents | 6 | 2018 | 3597 | 0.280 |
Why?
|
| Adaptation, Psychological | 2 | 2016 | 2666 | 0.270 |
Why?
|
| Analysis of Variance | 11 | 2010 | 6236 | 0.270 |
Why?
|
| Nanotechnology | 1 | 2012 | 714 | 0.270 |
Why?
|
| Dissociative Disorders | 3 | 2017 | 235 | 0.260 |
Why?
|
| Longitudinal Studies | 7 | 2024 | 14794 | 0.260 |
Why?
|
| Risk Factors | 21 | 2024 | 74976 | 0.260 |
Why?
|
| Motion Sickness | 2 | 2002 | 33 | 0.260 |
Why?
|
| Electroencephalography | 9 | 2023 | 6317 | 0.260 |
Why?
|
| Causality | 3 | 2018 | 1256 | 0.260 |
Why?
|
| Putamen | 2 | 2004 | 292 | 0.250 |
Why?
|
| Aging | 14 | 2003 | 8745 | 0.250 |
Why?
|
| Hydroxydopamines | 10 | 1990 | 59 | 0.250 |
Why?
|
| Clomipramine | 2 | 2002 | 50 | 0.250 |
Why?
|
| Child, Preschool | 19 | 2022 | 42683 | 0.250 |
Why?
|
| Violence | 1 | 2011 | 936 | 0.250 |
Why?
|
| Temporal Lobe | 2 | 2010 | 1728 | 0.240 |
Why?
|
| CA3 Region, Hippocampal | 2 | 2017 | 54 | 0.240 |
Why?
|
| Age Factors | 14 | 2019 | 18435 | 0.240 |
Why?
|
| Peer Group | 1 | 2010 | 698 | 0.230 |
Why?
|
| Personality Development | 2 | 1996 | 242 | 0.230 |
Why?
|
| Biogenic Monoamines | 3 | 2002 | 50 | 0.230 |
Why?
|
| Emotions | 5 | 2023 | 2768 | 0.230 |
Why?
|
| Sex Factors | 9 | 2019 | 10633 | 0.230 |
Why?
|
| Dose-Response Relationship, Drug | 15 | 2010 | 10765 | 0.210 |
Why?
|
| Olfactory Bulb | 6 | 1992 | 198 | 0.210 |
Why?
|
| Visual Perception | 2 | 2011 | 1407 | 0.210 |
Why?
|
| Mood Disorders | 3 | 2015 | 1129 | 0.210 |
Why?
|
| Psychological Tests | 1 | 2005 | 642 | 0.200 |
Why?
|
| Parkinson Disease, Secondary | 2 | 2020 | 121 | 0.200 |
Why?
|
| Dextroamphetamine | 4 | 1996 | 132 | 0.200 |
Why?
|
| Pilot Projects | 3 | 2020 | 8748 | 0.200 |
Why?
|
| Psychotic Disorders | 5 | 2017 | 3278 | 0.200 |
Why?
|
| Oxidopamine | 7 | 1998 | 170 | 0.200 |
Why?
|
| Activity Cycles | 7 | 2007 | 47 | 0.190 |
Why?
|
| Somatosensory Disorders | 1 | 2022 | 49 | 0.190 |
Why?
|
| Animals, Newborn | 12 | 2002 | 2683 | 0.190 |
Why?
|
| Borderline Personality Disorder | 3 | 2019 | 767 | 0.190 |
Why?
|
| Neostriatum | 2 | 2000 | 238 | 0.190 |
Why?
|
| Behavior, Animal | 7 | 2002 | 1862 | 0.190 |
Why?
|
| Electric Stimulation Therapy | 1 | 2008 | 637 | 0.190 |
Why?
|
| Antidepressive Agents, Tricyclic | 2 | 2002 | 430 | 0.190 |
Why?
|
| Maze Learning | 2 | 2002 | 481 | 0.190 |
Why?
|
| Sex Characteristics | 5 | 2013 | 2649 | 0.190 |
Why?
|
| Seasons | 4 | 2002 | 1524 | 0.190 |
Why?
|
| Sex Offenses | 2 | 2022 | 357 | 0.190 |
Why?
|
| Phenotype | 4 | 2021 | 16731 | 0.190 |
Why?
|
| Life Change Events | 7 | 2023 | 961 | 0.180 |
Why?
|
| Autoradiography | 6 | 2003 | 728 | 0.180 |
Why?
|
| Serotonin | 4 | 1999 | 1043 | 0.180 |
Why?
|
| Caudate Nucleus | 4 | 2014 | 391 | 0.180 |
Why?
|
| Child Behavior Disorders | 3 | 2016 | 813 | 0.180 |
Why?
|
| Hypothalamo-Hypophyseal System | 6 | 2019 | 702 | 0.170 |
Why?
|
| Ganglia | 1 | 2000 | 86 | 0.170 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 2 | 2021 | 1988 | 0.170 |
Why?
|
| Dopamine Agonists | 2 | 2004 | 347 | 0.170 |
Why?
|
| Norepinephrine | 7 | 2004 | 899 | 0.160 |
Why?
|
| Locomotion | 5 | 1997 | 388 | 0.160 |
Why?
|
| Cerebral Cortex | 8 | 2023 | 5831 | 0.160 |
Why?
|
| Animals | 58 | 2020 | 169335 | 0.160 |
Why?
|
| Body Temperature | 3 | 1999 | 781 | 0.160 |
Why?
|
| Alcohol Drinking | 1 | 2012 | 4045 | 0.160 |
Why?
|
| Fluoxetine | 2 | 1995 | 733 | 0.160 |
Why?
|
| Raphe Nuclei | 1 | 1999 | 104 | 0.160 |
Why?
|
| Reference Values | 8 | 2010 | 4940 | 0.160 |
Why?
|
| Facial Expression | 1 | 2023 | 515 | 0.160 |
Why?
|
| Catecholamines | 4 | 1998 | 389 | 0.160 |
Why?
|
| Anxiety Disorders | 3 | 2019 | 2749 | 0.160 |
Why?
|
| Anxiety, Separation | 1 | 2018 | 86 | 0.150 |
Why?
|
| Reactive Attachment Disorder | 1 | 2018 | 42 | 0.150 |
Why?
|
| Nerve Endings | 1 | 1998 | 103 | 0.150 |
Why?
|
| Ear Canal | 1 | 1999 | 149 | 0.150 |
Why?
|
| Retrospective Studies | 12 | 2023 | 81903 | 0.150 |
Why?
|
| Administration, Intranasal | 2 | 2017 | 485 | 0.150 |
Why?
|
| Cognition Disorders | 2 | 2017 | 3985 | 0.150 |
Why?
|
| Lithium | 3 | 1991 | 600 | 0.150 |
Why?
|
| Transcranial Magnetic Stimulation | 1 | 2008 | 1489 | 0.150 |
Why?
|
| Rats, Inbred Strains | 18 | 1991 | 2087 | 0.150 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2003 | 903 | 0.140 |
Why?
|
| Pituitary-Adrenal System | 5 | 2019 | 555 | 0.140 |
Why?
|
| Anxiety | 4 | 2020 | 4672 | 0.140 |
Why?
|
| Carbolines | 1 | 1999 | 295 | 0.140 |
Why?
|
| Patient Admission | 2 | 2002 | 1370 | 0.140 |
Why?
|
| Tetrahydronaphthalenes | 1 | 1997 | 85 | 0.140 |
Why?
|
| CA1 Region, Hippocampal | 1 | 2017 | 110 | 0.140 |
Why?
|
| Neurotoxins | 1 | 1998 | 240 | 0.140 |
Why?
|
| Stress, Physiological | 1 | 2004 | 1408 | 0.140 |
Why?
|
| Models, Neurological | 4 | 2022 | 1782 | 0.140 |
Why?
|
| Image Processing, Computer-Assisted | 6 | 2016 | 9080 | 0.140 |
Why?
|
| Brain Diseases | 2 | 2002 | 1558 | 0.140 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 1999 | 581 | 0.140 |
Why?
|
| Schizophrenia | 2 | 2015 | 6987 | 0.140 |
Why?
|
| Psychology, Experimental | 1 | 1996 | 4 | 0.140 |
Why?
|
| Rest | 3 | 2017 | 951 | 0.140 |
Why?
|
| Risk | 1 | 2008 | 9621 | 0.130 |
Why?
|
| Antipsychotic Agents | 5 | 1993 | 3081 | 0.130 |
Why?
|
| Image Interpretation, Computer-Assisted | 2 | 2010 | 3411 | 0.130 |
Why?
|
| Akathisia, Drug-Induced | 1 | 1995 | 66 | 0.130 |
Why?
|
| Defense Mechanisms | 1 | 2016 | 180 | 0.130 |
Why?
|
| Psychotropic Drugs | 2 | 2012 | 881 | 0.130 |
Why?
|
| Exercise Therapy | 1 | 2022 | 939 | 0.130 |
Why?
|
| Interview, Psychological | 2 | 2015 | 810 | 0.120 |
Why?
|
| Estrogens | 1 | 2002 | 1536 | 0.120 |
Why?
|
| Infant | 8 | 2023 | 36556 | 0.120 |
Why?
|
| Dopamine Antagonists | 6 | 2004 | 284 | 0.120 |
Why?
|
| Cerebrovascular Circulation | 2 | 2004 | 2734 | 0.120 |
Why?
|
| Photoperiod | 1 | 2015 | 141 | 0.120 |
Why?
|
| Injections, Intraperitoneal | 3 | 2012 | 412 | 0.120 |
Why?
|
| Case-Control Studies | 6 | 2018 | 22296 | 0.120 |
Why?
|
| Haloperidol | 3 | 1993 | 394 | 0.120 |
Why?
|
| Genetic Loci | 2 | 2024 | 2630 | 0.120 |
Why?
|
| Treatment Outcome | 9 | 2022 | 65480 | 0.110 |
Why?
|
| Maternal Behavior | 2 | 2023 | 307 | 0.110 |
Why?
|
| Nerve Degeneration | 1 | 1998 | 750 | 0.110 |
Why?
|
| Bromocriptine | 3 | 1989 | 93 | 0.110 |
Why?
|
| Memory | 3 | 2010 | 2209 | 0.110 |
Why?
|
| DNA Copy Number Variations | 1 | 2022 | 2055 | 0.110 |
Why?
|
| Sucking Behavior | 4 | 1983 | 27 | 0.110 |
Why?
|
| Family Health | 2 | 2010 | 1255 | 0.110 |
Why?
|
| Disease Susceptibility | 3 | 2007 | 1794 | 0.110 |
Why?
|
| Smell | 5 | 1984 | 261 | 0.110 |
Why?
|
| Time Factors | 13 | 2018 | 40261 | 0.110 |
Why?
|
| Interneurons | 1 | 1998 | 591 | 0.110 |
Why?
|
| Suicide | 3 | 2019 | 1606 | 0.110 |
Why?
|
| Photic Stimulation | 1 | 1999 | 2003 | 0.100 |
Why?
|
| Thioridazine | 2 | 1989 | 33 | 0.100 |
Why?
|
| Regression Analysis | 4 | 2017 | 6346 | 0.100 |
Why?
|
| Clathrin Heavy Chains | 1 | 2012 | 27 | 0.100 |
Why?
|
| Isothiocyanates | 1 | 2012 | 48 | 0.100 |
Why?
|
| Interpersonal Relations | 1 | 2020 | 1437 | 0.100 |
Why?
|
| Research Design | 1 | 2008 | 6214 | 0.100 |
Why?
|
| Socioeconomic Factors | 3 | 2012 | 7861 | 0.100 |
Why?
|
| Pentetic Acid | 1 | 2012 | 209 | 0.100 |
Why?
|
| Methoxyhydroxyphenylglycol | 2 | 2004 | 93 | 0.100 |
Why?
|
| Monoamine Oxidase Inhibitors | 2 | 1990 | 153 | 0.100 |
Why?
|
| Psychometrics | 3 | 2015 | 3066 | 0.100 |
Why?
|
| Fluorescein-5-isothiocyanate | 1 | 2012 | 222 | 0.100 |
Why?
|
| Substantia Nigra | 1 | 1993 | 347 | 0.100 |
Why?
|
| Testosterone | 1 | 2002 | 2493 | 0.090 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 2 | 2017 | 2831 | 0.090 |
Why?
|
| Stem Cell Transplantation | 1 | 2020 | 1602 | 0.090 |
Why?
|
| Hospitals, Psychiatric | 2 | 2002 | 317 | 0.090 |
Why?
|
| Cross-Sectional Studies | 7 | 2019 | 26395 | 0.090 |
Why?
|
| Dentate Gyrus | 1 | 2012 | 165 | 0.090 |
Why?
|
| Signal Processing, Computer-Assisted | 4 | 2013 | 1495 | 0.090 |
Why?
|
| 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine | 3 | 2004 | 50 | 0.090 |
Why?
|
| Executive Function | 2 | 2022 | 1405 | 0.090 |
Why?
|
| Mathematical Computing | 1 | 1990 | 142 | 0.090 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2012 | 690 | 0.090 |
Why?
|
| Trauma Severity Indices | 1 | 2012 | 479 | 0.090 |
Why?
|
| Refugees | 1 | 2018 | 615 | 0.090 |
Why?
|
| Entropy | 1 | 2010 | 211 | 0.090 |
Why?
|
| Impulsive Behavior | 1 | 2012 | 345 | 0.090 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2019 | 1902 | 0.080 |
Why?
|
| Alprazolam | 1 | 1990 | 103 | 0.080 |
Why?
|
| 3,4-Dihydroxyphenylacetic Acid | 3 | 1998 | 60 | 0.080 |
Why?
|
| Homovanillic Acid | 3 | 1998 | 73 | 0.080 |
Why?
|
| Injections, Intravenous | 1 | 2012 | 1379 | 0.080 |
Why?
|
| Wechsler Scales | 1 | 2010 | 258 | 0.080 |
Why?
|
| Drug Interactions | 5 | 2004 | 1418 | 0.080 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2012 | 1731 | 0.080 |
Why?
|
| Apomorphine | 7 | 1989 | 148 | 0.080 |
Why?
|
| Recovery of Function | 1 | 2020 | 2990 | 0.080 |
Why?
|
| Head Movements | 1 | 2010 | 153 | 0.080 |
Why?
|
| Genetic Predisposition to Disease | 5 | 2024 | 18068 | 0.080 |
Why?
|
| Excitatory Postsynaptic Potentials | 1 | 2010 | 369 | 0.080 |
Why?
|
| Periodicity | 1 | 1990 | 348 | 0.080 |
Why?
|
| Length of Stay | 1 | 2002 | 6526 | 0.080 |
Why?
|
| Nutritional Physiological Phenomena | 2 | 1989 | 360 | 0.080 |
Why?
|
| Panic | 1 | 1988 | 103 | 0.080 |
Why?
|
| Agoraphobia | 1 | 1988 | 177 | 0.080 |
Why?
|
| Eye Protective Devices | 1 | 2008 | 33 | 0.070 |
Why?
|
| Neurotransmitter Agents | 2 | 2002 | 663 | 0.070 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2020 | 1891 | 0.070 |
Why?
|
| Comorbidity | 3 | 2016 | 10592 | 0.070 |
Why?
|
| Thalamus | 1 | 2014 | 1049 | 0.070 |
Why?
|
| Intelligence | 1 | 2012 | 927 | 0.070 |
Why?
|
| Holocaust | 1 | 2007 | 37 | 0.070 |
Why?
|
| Stereoisomerism | 3 | 2006 | 611 | 0.070 |
Why?
|
| Angina Pectoris | 2 | 1988 | 957 | 0.070 |
Why?
|
| Protein Multimerization | 1 | 2012 | 968 | 0.070 |
Why?
|
| Levodopa | 2 | 1998 | 221 | 0.070 |
Why?
|
| Pulse Therapy, Drug | 1 | 2006 | 37 | 0.070 |
Why?
|
| Norepinephrine Plasma Membrane Transport Proteins | 1 | 2006 | 66 | 0.070 |
Why?
|
| Metabolic Clearance Rate | 2 | 2006 | 363 | 0.070 |
Why?
|
| Cocaine | 2 | 1989 | 947 | 0.070 |
Why?
|
| Body Mass Index | 1 | 2024 | 13055 | 0.070 |
Why?
|
| Pain | 1 | 2022 | 5100 | 0.070 |
Why?
|
| Delayed-Action Preparations | 2 | 2010 | 969 | 0.070 |
Why?
|
| Nerve Tissue Proteins | 1 | 1999 | 4413 | 0.070 |
Why?
|
| Placebo Effect | 1 | 2010 | 518 | 0.070 |
Why?
|
| Alopecia | 1 | 1991 | 416 | 0.070 |
Why?
|
| Chromatography, High Pressure Liquid | 3 | 1999 | 1536 | 0.070 |
Why?
|
| Aptitude Tests | 1 | 2006 | 20 | 0.070 |
Why?
|
| Placebos | 3 | 2002 | 1667 | 0.070 |
Why?
|
| Avoidance Learning | 3 | 1984 | 248 | 0.060 |
Why?
|
| Personality Assessment | 3 | 1996 | 646 | 0.060 |
Why?
|
| Metronidazole | 1 | 1987 | 236 | 0.060 |
Why?
|
| Behavior | 1 | 1989 | 543 | 0.060 |
Why?
|
| Phobic Disorders | 1 | 1988 | 441 | 0.060 |
Why?
|
| Benzazepines | 4 | 2004 | 308 | 0.060 |
Why?
|
| Haplorhini | 1 | 2006 | 523 | 0.060 |
Why?
|
| Social Environment | 3 | 2017 | 1015 | 0.060 |
Why?
|
| Blood-Brain Barrier | 1 | 2012 | 1036 | 0.060 |
Why?
|
| Education | 1 | 2008 | 533 | 0.060 |
Why?
|
| Neurogenesis | 1 | 2012 | 865 | 0.060 |
Why?
|
| Genome-Wide Association Study | 5 | 2024 | 12801 | 0.060 |
Why?
|
| Quinpirole | 2 | 1997 | 27 | 0.060 |
Why?
|
| Reproducibility of Results | 4 | 2015 | 20245 | 0.060 |
Why?
|
| Double-Blind Method | 5 | 2008 | 12467 | 0.060 |
Why?
|
| Autonomic Nervous System | 1 | 2010 | 709 | 0.060 |
Why?
|
| Choice Behavior | 2 | 2010 | 848 | 0.060 |
Why?
|
| Synaptophysin | 1 | 2004 | 138 | 0.060 |
Why?
|
| Nerve Fibers | 1 | 2008 | 709 | 0.060 |
Why?
|
| Personality Inventory | 2 | 2006 | 1018 | 0.060 |
Why?
|
| Suicide, Attempted | 1 | 2013 | 1409 | 0.060 |
Why?
|
| Protein Conformation | 1 | 2012 | 3956 | 0.060 |
Why?
|
| Demography | 1 | 2009 | 1642 | 0.060 |
Why?
|
| Receptors, GABA-A | 1 | 1988 | 625 | 0.060 |
Why?
|
| Family Relations | 1 | 2006 | 318 | 0.060 |
Why?
|
| Prevalence | 5 | 2016 | 15879 | 0.060 |
Why?
|
| Child of Impaired Parents | 1 | 2007 | 462 | 0.060 |
Why?
|
| Models, Statistical | 4 | 2012 | 5110 | 0.050 |
Why?
|
| Antidepressive Agents | 2 | 2010 | 2913 | 0.050 |
Why?
|
| Disease Models, Animal | 2 | 2008 | 18354 | 0.050 |
Why?
|
| Blood Volume | 1 | 2004 | 546 | 0.050 |
Why?
|
| Learning | 2 | 2017 | 1760 | 0.050 |
Why?
|
| Chronobiology Phenomena | 2 | 2007 | 29 | 0.050 |
Why?
|
| Middle Aged | 26 | 2024 | 223737 | 0.050 |
Why?
|
| Dizocilpine Maleate | 1 | 2003 | 171 | 0.050 |
Why?
|
| Radioligand Assay | 1 | 2003 | 366 | 0.050 |
Why?
|
| Severity of Illness Index | 5 | 2017 | 15951 | 0.050 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2008 | 4076 | 0.050 |
Why?
|
| Gyrus Cinguli | 1 | 2009 | 1135 | 0.050 |
Why?
|
| Incest | 1 | 2002 | 19 | 0.050 |
Why?
|
| Animals, Suckling | 2 | 1979 | 69 | 0.050 |
Why?
|
| Glucocorticoids | 1 | 2012 | 2167 | 0.050 |
Why?
|
| Obesity | 1 | 2024 | 13091 | 0.050 |
Why?
|
| Sulfates | 1 | 1983 | 379 | 0.050 |
Why?
|
| Models, Molecular | 1 | 2012 | 5404 | 0.050 |
Why?
|
| Species Specificity | 1 | 2006 | 2417 | 0.050 |
Why?
|
| Age of Onset | 1 | 2009 | 3346 | 0.050 |
Why?
|
| Drug Administration Schedule | 2 | 2006 | 4862 | 0.050 |
Why?
|
| Food Coloring Agents | 1 | 1980 | 7 | 0.050 |
Why?
|
| Social Class | 1 | 2010 | 2009 | 0.050 |
Why?
|
| Reaction Time | 3 | 2004 | 2101 | 0.050 |
Why?
|
| Radiography | 1 | 2012 | 6991 | 0.050 |
Why?
|
| Mothers | 4 | 2023 | 2209 | 0.050 |
Why?
|
| Individuality | 1 | 2002 | 307 | 0.050 |
Why?
|
| Neurons | 2 | 1999 | 9519 | 0.050 |
Why?
|
| Software | 2 | 1996 | 4479 | 0.040 |
Why?
|
| Body Temperature Regulation | 2 | 1999 | 292 | 0.040 |
Why?
|
| Health Status | 1 | 2013 | 4095 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2016 | 14752 | 0.040 |
Why?
|
| Nanoparticles | 1 | 2012 | 1989 | 0.040 |
Why?
|
| Rats, Nude | 1 | 2020 | 106 | 0.040 |
Why?
|
| Orchiectomy | 1 | 2002 | 468 | 0.040 |
Why?
|
| Weaning | 2 | 1999 | 102 | 0.040 |
Why?
|
| Pheromones | 1 | 1980 | 93 | 0.040 |
Why?
|
| Ovariectomy | 1 | 2002 | 613 | 0.040 |
Why?
|
| Social Isolation | 2 | 1981 | 366 | 0.040 |
Why?
|
| Habituation, Psychophysiologic | 2 | 1996 | 147 | 0.040 |
Why?
|
| Diagnosis, Differential | 4 | 2005 | 13021 | 0.040 |
Why?
|
| Animal Population Groups | 1 | 1978 | 12 | 0.040 |
Why?
|
| Inpatients | 2 | 2016 | 2569 | 0.040 |
Why?
|
| Litter Size | 1 | 1978 | 49 | 0.040 |
Why?
|
| Zinc | 1 | 1983 | 677 | 0.040 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2024 | 16053 | 0.040 |
Why?
|
| Regional Blood Flow | 1 | 2002 | 1500 | 0.040 |
Why?
|
| Vision, Monocular | 1 | 1999 | 71 | 0.040 |
Why?
|
| Memory Disorders | 1 | 2006 | 1202 | 0.040 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 2 | 1999 | 1106 | 0.040 |
Why?
|
| Statistics as Topic | 1 | 2004 | 2360 | 0.040 |
Why?
|
| Tyrosine 3-Monooxygenase | 1 | 1999 | 368 | 0.040 |
Why?
|
| Salicylamides | 1 | 1997 | 31 | 0.040 |
Why?
|
| Eyeglasses | 1 | 1999 | 138 | 0.040 |
Why?
|
| Tetrodotoxin | 1 | 1998 | 243 | 0.030 |
Why?
|
| Speech Perception | 1 | 2002 | 512 | 0.030 |
Why?
|
| Lactation | 1 | 1979 | 392 | 0.030 |
Why?
|
| Monitoring, Physiologic | 3 | 1989 | 1798 | 0.030 |
Why?
|
| Brain Damage, Chronic | 1 | 1998 | 267 | 0.030 |
Why?
|
| Biological Evolution | 1 | 2003 | 1077 | 0.030 |
Why?
|
| Survivors | 1 | 2007 | 2383 | 0.030 |
Why?
|
| Growth | 1 | 1978 | 366 | 0.030 |
Why?
|
| Prognosis | 2 | 2012 | 30046 | 0.030 |
Why?
|
| Body Weight | 3 | 2002 | 4628 | 0.030 |
Why?
|
| Sleep, REM | 1 | 1999 | 595 | 0.030 |
Why?
|
| Polymorphism, Genetic | 1 | 2006 | 4251 | 0.030 |
Why?
|
| Piperazines | 1 | 1986 | 2553 | 0.030 |
Why?
|
| Mental Health | 2 | 2023 | 3275 | 0.030 |
Why?
|
| Models, Animal | 1 | 2002 | 2122 | 0.030 |
Why?
|
| Students | 1 | 2006 | 1744 | 0.030 |
Why?
|
| Hair | 1 | 2019 | 509 | 0.030 |
Why?
|
| Self Report | 2 | 2020 | 3773 | 0.030 |
Why?
|
| Escape Reaction | 3 | 1984 | 57 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 2006 | 5801 | 0.030 |
Why?
|
| Epilepsy | 1 | 2010 | 3326 | 0.030 |
Why?
|
| Aged | 12 | 2010 | 171786 | 0.030 |
Why?
|
| Videotape Recording | 1 | 1996 | 335 | 0.030 |
Why?
|
| Infant, Newborn | 3 | 2017 | 26428 | 0.030 |
Why?
|
| Acting Out | 1 | 1994 | 16 | 0.030 |
Why?
|
| Combat Disorders | 1 | 1996 | 301 | 0.030 |
Why?
|
| Interior Design and Furnishings | 1 | 1994 | 34 | 0.030 |
Why?
|
| Genome | 1 | 2022 | 1754 | 0.030 |
Why?
|
| Color | 1 | 1995 | 297 | 0.030 |
Why?
|
| Dangerous Behavior | 1 | 1994 | 65 | 0.030 |
Why?
|
| Environment | 2 | 1996 | 1122 | 0.030 |
Why?
|
| Tissue Distribution | 1 | 1998 | 2298 | 0.030 |
Why?
|
| Data Interpretation, Statistical | 1 | 2004 | 2714 | 0.030 |
Why?
|
| Patient Isolation | 1 | 1994 | 100 | 0.030 |
Why?
|
| Image Enhancement | 1 | 2004 | 2898 | 0.030 |
Why?
|
| Coronary Disease | 1 | 1988 | 5919 | 0.030 |
Why?
|
| Deoxyglucose | 3 | 1983 | 333 | 0.030 |
Why?
|
| Growth Hormone | 1 | 1995 | 573 | 0.030 |
Why?
|
| Temperament | 1 | 1995 | 301 | 0.030 |
Why?
|
| Forkhead Transcription Factors | 1 | 2020 | 1625 | 0.030 |
Why?
|
| Phenanthridines | 1 | 1991 | 50 | 0.020 |
Why?
|
| Light | 2 | 1995 | 1355 | 0.020 |
Why?
|
| United States | 2 | 2018 | 73186 | 0.020 |
Why?
|
| Dihydroxyphenylalanine | 1 | 1991 | 74 | 0.020 |
Why?
|
| Ergolines | 1 | 1991 | 56 | 0.020 |
Why?
|
| Task Performance and Analysis | 1 | 1996 | 771 | 0.020 |
Why?
|
| Pregnancy | 4 | 2004 | 30265 | 0.020 |
Why?
|
| Vitamin B 12 | 1 | 1994 | 529 | 0.020 |
Why?
|
| Desipramine | 3 | 1987 | 183 | 0.020 |
Why?
|
| Tanzania | 1 | 2016 | 1407 | 0.020 |
Why?
|
| Contrast Media | 1 | 2004 | 5334 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2008 | 15471 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2014 | 41808 | 0.020 |
Why?
|
| Dopamine Agents | 1 | 1991 | 188 | 0.020 |
Why?
|
| Social Behavior | 1 | 2017 | 1146 | 0.020 |
Why?
|
| Memory, Short-Term | 1 | 2017 | 1008 | 0.020 |
Why?
|
| Chronic Disease | 2 | 2002 | 9384 | 0.020 |
Why?
|
| Lithium Carbonate | 1 | 1991 | 179 | 0.020 |
Why?
|
| Microcomputers | 1 | 1990 | 139 | 0.020 |
Why?
|
| Software Design | 1 | 1990 | 173 | 0.020 |
Why?
|
| Propylamines | 1 | 2010 | 161 | 0.020 |
Why?
|
| Somatoform Disorders | 1 | 1993 | 425 | 0.020 |
Why?
|
| Massachusetts | 1 | 2002 | 8894 | 0.020 |
Why?
|
| Least-Squares Analysis | 1 | 1990 | 367 | 0.020 |
Why?
|
| Hot Temperature | 1 | 1996 | 1441 | 0.020 |
Why?
|
| Adrenergic Uptake Inhibitors | 1 | 2010 | 186 | 0.020 |
Why?
|
| Psychomotor Agitation | 1 | 1992 | 307 | 0.020 |
Why?
|
| Ambulatory Care | 2 | 1998 | 2784 | 0.020 |
Why?
|
| Phenelzine | 1 | 1988 | 28 | 0.020 |
Why?
|
| Tranylcypromine | 1 | 1988 | 30 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2013 | 54962 | 0.020 |
Why?
|
| Septal Nuclei | 1 | 1989 | 84 | 0.020 |
Why?
|
| Repressor Proteins | 1 | 2020 | 2986 | 0.020 |
Why?
|
| Blood Glucose | 1 | 1983 | 6435 | 0.020 |
Why?
|
| Mental Recall | 1 | 1995 | 1226 | 0.020 |
Why?
|
| Perphenazine | 1 | 1988 | 33 | 0.020 |
Why?
|
| Sympatholytics | 1 | 1988 | 82 | 0.020 |
Why?
|
| Models, Biological | 1 | 2004 | 9499 | 0.020 |
Why?
|
| Nonlinear Dynamics | 1 | 2010 | 494 | 0.020 |
Why?
|
| Buspirone | 1 | 1988 | 80 | 0.020 |
Why?
|
| Diltiazem | 1 | 1988 | 132 | 0.020 |
Why?
|
| Nifedipine | 1 | 1988 | 220 | 0.020 |
Why?
|
| Injections, Intraventricular | 1 | 1988 | 227 | 0.020 |
Why?
|
| Hydroxyindoleacetic Acid | 1 | 1986 | 94 | 0.020 |
Why?
|
| Adult Children | 1 | 2007 | 104 | 0.020 |
Why?
|
| Conditioning, Classical | 2 | 1987 | 368 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 2010 | 1586 | 0.020 |
Why?
|
| Nitrates | 1 | 1988 | 260 | 0.020 |
Why?
|
| Fluphenazine | 1 | 1985 | 35 | 0.020 |
Why?
|
| Veterans | 1 | 2019 | 2672 | 0.020 |
Why?
|
| Butyrophenones | 1 | 1985 | 15 | 0.020 |
Why?
|
| Affective Disorders, Psychotic | 1 | 1986 | 187 | 0.010 |
Why?
|
| Boston | 1 | 2017 | 9377 | 0.010 |
Why?
|
| Calcium Channel Blockers | 1 | 1988 | 691 | 0.010 |
Why?
|
| Zinc Fingers | 1 | 2006 | 577 | 0.010 |
Why?
|
| Stereotyped Behavior | 4 | 1986 | 134 | 0.010 |
Why?
|
| Dietary Carbohydrates | 1 | 1989 | 896 | 0.010 |
Why?
|
| Genomics | 1 | 2020 | 5928 | 0.010 |
Why?
|
| Zinc Sulfate | 1 | 1983 | 18 | 0.010 |
Why?
|
| User-Computer Interface | 1 | 1990 | 1406 | 0.010 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 1988 | 628 | 0.010 |
Why?
|
| Dietary Proteins | 1 | 1989 | 960 | 0.010 |
Why?
|
| Indoles | 1 | 1991 | 1836 | 0.010 |
Why?
|
| Dementia | 2 | 1990 | 2741 | 0.010 |
Why?
|
| Clinical Trials as Topic | 2 | 1997 | 8055 | 0.010 |
Why?
|
| Psoriasis | 1 | 1991 | 926 | 0.010 |
Why?
|
| Fixation, Ocular | 1 | 2004 | 243 | 0.010 |
Why?
|
| Amino Acids | 1 | 1989 | 1716 | 0.010 |
Why?
|
| Prolactin | 1 | 2004 | 627 | 0.010 |
Why?
|
| Nervous System Diseases | 1 | 1993 | 1665 | 0.010 |
Why?
|
| Alzheimer Disease | 2 | 1995 | 8760 | 0.010 |
Why?
|
| Drug Therapy, Combination | 2 | 1988 | 6320 | 0.010 |
Why?
|
| Sleep | 1 | 1997 | 4820 | 0.010 |
Why?
|
| Conditioning, Operant | 1 | 1982 | 308 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2002 | 24333 | 0.010 |
Why?
|
| Energy Intake | 1 | 1989 | 2146 | 0.010 |
Why?
|
| Dexamethasone | 1 | 1988 | 1965 | 0.010 |
Why?
|
| Disease Progression | 1 | 1998 | 13674 | 0.010 |
Why?
|
| Administration, Oral | 1 | 1988 | 4040 | 0.010 |
Why?
|
| Algorithms | 2 | 2010 | 14201 | 0.010 |
Why?
|
| Human Growth Hormone | 1 | 2004 | 651 | 0.010 |
Why?
|
| Appetitive Behavior | 1 | 1978 | 39 | 0.010 |
Why?
|
| Cerebrovascular Disorders | 1 | 1986 | 1486 | 0.010 |
Why?
|
| Anticonvulsants | 1 | 1988 | 1924 | 0.010 |
Why?
|
| Cognition | 1 | 2016 | 7081 | 0.010 |
Why?
|
| Catalepsy | 2 | 1988 | 31 | 0.010 |
Why?
|
| Cortical Synchronization | 1 | 1998 | 78 | 0.010 |
Why?
|
| Follow-Up Studies | 2 | 2010 | 39394 | 0.010 |
Why?
|
| Acute Disease | 1 | 1988 | 7245 | 0.010 |
Why?
|
| Fourier Analysis | 1 | 1998 | 441 | 0.010 |
Why?
|
| Nipples | 1 | 1978 | 229 | 0.010 |
Why?
|
| Stomach | 1 | 1980 | 702 | 0.010 |
Why?
|
| Baths | 1 | 1996 | 52 | 0.010 |
Why?
|
| Base Sequence | 1 | 2006 | 12430 | 0.010 |
Why?
|
| Alleles | 1 | 2006 | 6901 | 0.010 |
Why?
|
| Iraq | 1 | 1995 | 93 | 0.010 |
Why?
|
| Sensory Receptor Cells | 1 | 1980 | 508 | 0.010 |
Why?
|
| Vibration | 1 | 1977 | 335 | 0.010 |
Why?
|
| Epinephrine | 1 | 1998 | 794 | 0.010 |
Why?
|
| Milieu Therapy | 1 | 1994 | 3 | 0.010 |
Why?
|
| Protein Binding | 1 | 2006 | 9344 | 0.010 |
Why?
|
| Aged, 80 and over | 3 | 1991 | 59739 | 0.010 |
Why?
|
| Hospitalization | 1 | 1994 | 10847 | 0.010 |
Why?
|
| DNA | 1 | 2006 | 7214 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2006 | 7609 | 0.010 |
Why?
|
| Israel | 1 | 1995 | 726 | 0.010 |
Why?
|
| Oxygen | 1 | 2004 | 4272 | 0.010 |
Why?
|
| Wakefulness | 1 | 1999 | 1284 | 0.010 |
Why?
|
| Amitriptyline | 1 | 1992 | 112 | 0.010 |
Why?
|
| Sleep Stages | 1 | 1996 | 706 | 0.010 |
Why?
|
| Exploratory Behavior | 2 | 1984 | 272 | 0.010 |
Why?
|
| Sexual Behavior, Animal | 1 | 1992 | 120 | 0.010 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 1993 | 877 | 0.010 |
Why?
|
| Cross-Over Studies | 1 | 1997 | 2108 | 0.010 |
Why?
|
| Italy | 1 | 1993 | 856 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 1997 | 3438 | 0.010 |
Why?
|
| Tritium | 1 | 1990 | 707 | 0.010 |
Why?
|
| Electrophysiology | 1 | 1993 | 1266 | 0.010 |
Why?
|
| Domperidone | 1 | 1989 | 24 | 0.010 |
Why?
|
| Spiperone | 1 | 1988 | 31 | 0.010 |
Why?
|
| Quinuclidinyl Benzilate | 1 | 1988 | 19 | 0.010 |
Why?
|
| Polysomnography | 1 | 1996 | 1871 | 0.000 |
Why?
|
| Prazosin | 1 | 1988 | 95 | 0.000 |
Why?
|
| Evoked Potentials | 1 | 1995 | 1058 | 0.000 |
Why?
|
| Gene Expression Regulation | 1 | 2006 | 11932 | 0.000 |
Why?
|
| Receptors, Adrenergic | 1 | 1988 | 155 | 0.000 |
Why?
|
| Receptors, Muscarinic | 1 | 1988 | 157 | 0.000 |
Why?
|
| Anesthesia | 1 | 1978 | 1596 | 0.000 |
Why?
|
| Transcription Factors | 1 | 2006 | 12174 | 0.000 |
Why?
|
| Psychotherapy | 1 | 1995 | 1654 | 0.000 |
Why?
|
| Terminology as Topic | 1 | 1993 | 1541 | 0.000 |
Why?
|
| Droperidol | 1 | 1985 | 21 | 0.000 |
Why?
|
| Headache | 1 | 1993 | 1264 | 0.000 |
Why?
|
| Schizophrenic Psychology | 1 | 1992 | 1651 | 0.000 |
Why?
|
| Models, Theoretical | 1 | 1996 | 3580 | 0.000 |
Why?
|
| Family | 1 | 1995 | 3208 | 0.000 |
Why?
|
| Half-Life | 1 | 1985 | 651 | 0.000 |
Why?
|
| Subcellular Fractions | 1 | 1984 | 527 | 0.000 |
Why?
|
| Random Allocation | 1 | 1988 | 2394 | 0.000 |
Why?
|
| Pentanols | 1 | 1982 | 4 | 0.000 |
Why?
|
| Muridae | 1 | 1982 | 55 | 0.000 |
Why?
|
| Generalization, Stimulus | 1 | 1982 | 13 | 0.000 |
Why?
|
| Association Learning | 1 | 1982 | 221 | 0.000 |
Why?
|
| Posture | 1 | 1985 | 957 | 0.000 |
Why?
|
| Recurrence | 1 | 1993 | 8513 | 0.000 |
Why?
|
| Exercise Test | 1 | 1988 | 2187 | 0.000 |
Why?
|
| Thermosensing | 1 | 1980 | 56 | 0.000 |
Why?
|
| Cattle | 1 | 1984 | 3819 | 0.000 |
Why?
|
| Hemodynamics | 1 | 1988 | 4199 | 0.000 |
Why?
|
| Kinetics | 1 | 1984 | 6332 | 0.000 |
Why?
|
| Binding Sites | 1 | 1984 | 6023 | 0.000 |
Why?
|
| Cues | 1 | 1980 | 878 | 0.000 |
Why?
|
| Electrocardiography | 1 | 1988 | 6413 | 0.000 |
Why?
|
| Incidence | 1 | 1993 | 21547 | 0.000 |
Why?
|